Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPI-628
- Development stage
- Preclinical
- Lead developer
- EpiBiologics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
EPI-628 is an antibody-based degrader antibody-drug conjugate (ADC) developed by EpiBiologics. It specifically targets the c-Met (hepatocyte growth factor receptor) protein, which is frequently overexpressed or mutated in various solid tumors. Utilizing the EpiTAC platform, EPI-628 is designed to both induce the degradation of the c-Met receptor and deliver a potent cytotoxic payload directly to cancer cells. This dual mechanism of action aims to overcome resistance associated with traditional c-Met inhibitors and standard ADCs. The drug is currently in IND-enabling studies for the treatment of colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and gastric cancer.
- Other names
- c-Met EpiTAC programEpiTAC bispecific antibody degrader of c-Metc-Met bispecific antibody-ADC
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on EPI-628.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPI-628.